Bavarian Nordic — September 2017
-
-
33,9 måneder samlet - det er vel fint
-
Disse data ser meget fine ud, med mindre placebo-gruppen denne gang har performet væsentlig bedre end ved tidligere studier.
-
Og det kan man desværre ikke udelukke. Men er det sandsynligt?
-
Based on patients’ ratings of their pain, the effect of trialled drugs in relieving symptoms stayed the same over the 23-year period—but placebo responses rose. In 1996, patients in clinical trials reported that drugs relieved their pain by 27% more than did a placebo. But by 2013, that gap had slipped to just 9%. The phenomenon is driven by 35 US trials; among trials in Europe, Asia and elsewhere, there was no significant change in placebo reponses.The analysis is in press in the journal Pain.
-
Novod siger spændende data -
-
Nordea: So unless the placebo/control group ends up performing vastlydifferently than in recent trials with Xtandi and Ipilimumab, OS could be significantly increased with PROSTVAC. We are cautious in drawing too firm conclusions, but we find Dr Gulley’s presentation intriguing ahead of the final PROSTVAC ph III read-out.
-
Dette må være et godt tegn, så vi kan sove roligere indtil de endelige resultater. Ingen markant reaktion på markedet. Shorterne må da blive lidt bekymrede over di
sse data -
-
Vel ikke overrakskende at der er et fald i receptudskrivelserne i industriferien?
-
godt. Så er vi enige.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind